Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) dropped 6.8% on Tuesday after an insider sold shares in the company. The stock traded as low as $126.56 and last traded at $128.01. Approximately 1,306,200 shares traded hands during trading, an increase of 14% from the average daily volume of 1,150,462 shares. The stock had previously closed at $137.31.

Specifically, Director Dennis A. Ausiello sold 20,000 shares of the firm’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $130.00, for a total value of $2,600,000.00. Following the sale, the director now directly owns 20,000 shares in the company, valued at approximately $2,600,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, President Barry E. Greene sold 85,316 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $125.00, for a total transaction of $10,664,500.00. The disclosure for this sale can be found here. Insiders sold a total of 393,212 shares of company stock worth $48,109,436 over the last 90 days. Company insiders own 4.30% of the company’s stock.

ALNY has been the topic of a number of analyst reports. Needham & Company LLC restated a “buy” rating and issued a $85.00 price objective (down from $98.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 7th. Jefferies Group set a $102.00 price objective on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 25th. BidaskClub lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 16th. Credit Suisse Group reiterated a “buy” rating and set a $96.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, August 11th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $56.00 price target (up from $47.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, August 10th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and seventeen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $121.85.

The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.23) by ($0.11). The firm had revenue of $17.10 million during the quarter, compared to analysts’ expectations of $28.15 million. Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The firm’s revenue was up 24.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.21) EPS. research analysts expect that Alnylam Pharmaceuticals, Inc. will post -5.21 earnings per share for the current year.

Several large investors have recently modified their holdings of ALNY. QS Investors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 59.7% in the second quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 900 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Alnylam Pharmaceuticals by 7.0% in the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 167 shares in the last quarter. CIBC Asset Management Inc purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at about $221,000. Neuberger Berman Group LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at about $229,000. Finally, Fayerweather Charles purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at about $230,000. 88.43% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/07/alnylam-pharmaceuticals-alny-shares-down-6-8-on-insider-selling.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.